Treating rheumatoid arthritis

Area of Science:

• Rheumatology
• Pharmacology

Background:

• Rheumatoid arthritis (RA) impacts 1% of the global population, causing joint dysfunction and bone damage.
• Current RA treatments include disease-modifying antirheumatic drugs (DMARDs), with methotrexate being a primary option.
• Evolving treatment landscapes necessitate careful consideration of efficacy, safety, and cost.

Approach:

• A comprehensive literature review was conducted to evaluate RA treatment strategies.
• Comparative analysis focused on methotrexate monotherapy versus combination DMARD therapies.
• Key decision factors included treatment efficacy, adverse event profiles, and economic considerations.

Key Points:

• Methotrexate monotherapy demonstrates a favorable efficacy and safety profile for RA management.
• Combination therapies involving methotrexate and other DMARDs did not consistently show superior outcomes.
• Cost-effectiveness remains a critical factor in RA treatment selection.

Conclusions:

• Methotrexate monotherapy is supported as the current best-practice standard for rheumatoid arthritis treatment.
• Evidence suggests that monotherapy provides a more advantageous risk-benefit ratio compared to combination therapies.
• Further research may explore personalized treatment approaches based on individual patient factors.